<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=791414221315877&amp;ev=PageView&amp;noscript=1">

Med-X Company Updates

NEW: Med-X Closing Regulation A+ Offering on April 22nd, 2022

 

Med-X Engages with Investor Relations Group, MZ North America as Planning to Access the Awaiting $100MM in Capital from Global Emerging Markets Continues

 

Med-X, Inc. Receives Patent on Nature-Cide Insecticidal Soil

 

Med-X, Inc. Relaunches its Regulation A+ Crowdfunding Offering in Preparation for a Public Market Listing to Access its $100 Million Capital Commitment

 

Med-X, Inc. Secures $100 Million Expansion Capital Commitment from Global Emerging Markets (GEM)

 

Med-X, Inc. Management Team Signs $86 Million Dollar Non-Binding Term Sheet to Bolster Long Term Growth and Prepare the Company for a Potential Public Listing

 

Momentum for Med-X Continues to Grow on Multiple Fronts as Investment Banks Get More Involved

 

Update: 1-22-2021 - Nature-Cide Begins Movement Into Mexico and Australia

 

12-28-2020 - Med-X, Inc. Grows in 2020 with Essential Products, Reaches 1 Million in Revenue and Gears up to Continue Expansion in 2021

 

Special Message from COO Matthew Mills: All Shareholders Need to Get Organized and Get Involved as the Company Growth Plan and Strategy Continues

 

Over 1100 Shareholders Have Successfully Accessed Their Med-X Shareholder Dashboard

 

US Capital Global Engages With Med-X, Inc. as Strategic Advisor for 10MM Capital Formation

 

Med-X Engages with Eurasian Capital to Support Planned Path to IPO

 

Med-X Management Team Begins Planning an IPO to Support and Bolster Growth Initiatives

 

Med-X Launches Regulation CF Crowdfunding Offering on TruCrowd as it Continues to Grow as an Essential Supply Business

 

SEC Extends K1 Filling Deadline Due to Covid-19

 

As an Essential Business Med-X Keeps Fulfilling Orders and Continues to Service Customers

 

Company Positioned to Sustain Revenue During Covid-19 Pandemic

 

$1,000,000 Raised Milestone Reached on the New Offering

 

Two Year Independent Study in Florida Finds Nature-Cide as the Top Performing Pesticide in a Side-by-Side Study Against Top Selling Synthetic Products for Mosquito Control

 

2019 Year-End Review and Outlook for 2020

 

Med-X, Inc. Surpasses 2018 Revenue During the 4th Quarter of 2019 While in Final Stages of it’s First Pest Control Service Acquisition

 

Nature-Cide Shines at PestWorld 2019

 

Strict International Regulations on Pesticides Continue to Fuel Nature-Cide Expansion and Growth Outlook

 

REGULATION A+ Offering is now closed

Recent Posts

Posts by Tag